Fueled by Growing Demand, Spherix Global Insights Introduces Ophthalmology to Expert Suite of Independent Market Research and Intelligence Services
The new addition ties Spherix’s unique approach to syndicated research to a highly dynamic market, filling the white space for pharma stakeholders in ophthalmology EXTON, Pa., November 11, 2021 /PRNewswire/ — Spherix Global Insights is a recognized market intelligence firm providing independent coverage of select specialty markets. This week, the company officially cut the ribbon […]
The Very Slow Roll of Biogen’s Aduhelm: Neurologists Weigh in on Patients, Practices and Payments Amid Ongoing Media Storm
From: Endpoints News By: Beth Snyder Bulik Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including […]
Ocrevus Still Top Therapy for Progressive MS Forms, Report Finds
From: Multiple Sclerosis News Today By: Marisa Wexler MS Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for progressive forms of multiple sclerosis (MS), including primary progressive MS (PPMS) and secondary progressive MS (SPMS), according to an analysis from the market intelligence firm Spherix Global Insights. However, other therapies are “gaining traction” among SPMS patients, the report finds…(read more)
Genentech’s Trailblazing Ocrevus Maintains Leading Position in the Progressive Multiple Sclerosis Space, But Emerging Bruton’s Tyrosine Kinase Inhibitors Could Threaten Its Long-Term Dominance
New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the US treatment algorithm EXTON, Pa., November 4, 2021/PRNewswire/ – Although the population of multiple sclerosis (MS) patients with progressive disease remains underserved, several recent approvals for relapsing MS (RMS), which includes active secondary progressive […]
Novel Agents in Systemic Lupus Erythematosus (AstraZeneca’s anifrolumab) and Lupus Nephritis (Aurinia Pharmaceutical’s voclosporin and GSK’s belimumab) Introduce Paradigm Shifts
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well as several pipeline agents (including Eli Lilly’s baricitinib in SLE and Roche-Genentech’s obinutuzumab in LN) garnering high interest among rheumatologists and nephrologists November 4, 2021, EXTON, PA – After nearly a decade of stagnant innovation […]
Disparities in Kidney Care: Where Care Needs to Be Equal
Authors: Meghan Staudt, Skylar Malone, Tucker Hurtado BACKGROUND: Disparities in kidney care are widespread and gaining more attention. This research focuses on care differences that existed between home hemodialysis (HHD) and in-center hemodialysis (ICHD) patient from 2017 to 2020. METHODS: Using a HIPAA-compliant, online chart review tool, nephrologists submitted de-identified clinical and non-clinical demographic information […]
Post-Launch Insights Point to Four Key Factors That Could Drive Future Use of Biogen/Eisai’s Aduhelm in Alzheimer’s Disease
What the Aduhelm manufacturers and others with agents in the pipeline can learn from early launch metrics EXTON, Pa., October 7, 2021 /PRNewswire/ — At three months post-launch, the high expectations for Biogen/Eisai’s Aduhelm in Alzheimer’s disease have not quite materialized. Neurologist-reported patient share for the drug, as well as the percentage of neurologists who have ever […]
AbbVie Pressures Biohaven in Migraine Prevention with FDA Approval for its CGRP Blockbuster-to-be Qulipta
From: FiercePharma By: Angus Liu Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations. Doctors’ initial […]
Initial Launch Execution Fails to Impress for Biogen’s Aduhelm – the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer’s Disease – as the Controversy Churn Continues
One month post launch, Spherix data indicates that Aduhelm (aducanumab-avwa) awareness easily outpaces other key performance indicators, including degree of advance, anticipated patient candidacy, prescriber uptake, and launch execution among US neurologists EXTON, Pa., July 14, 2021/PRNewswire/ — As expected with the recent media maelstrom surrounding its June 7th approval, unaided and aided awareness of […]
Bristol Myers Squibb’s Zeposia and Novartis’ Mayzent Have Both Experienced Strong Launches in Canada, But Spherix Data Uncover Numerous Internal and External Threats for Sustained Success
Neurologists in Canada are receptive to having a fourth S1P receptor modulator option in Janssen’s Ponvory, although increasing the clinical relevance of the agent’s comparative efficacy to Sanofi Genzyme’s Aubagio and fatigue secondary endpoint data is a must for any notable uptake EXTON, Pa., May 25, 2021/PRNewswire – Over the past two years, two new […]
